News

Thiogenesis Therapeutics to Present at UMDF's Mitochondrial Medicine 2025 Conference
June 20, 2025) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) (OTCQX: TTIPF) ("Thiogenesis" or the "Company"), a clinical-stage biopharmaceutical company developing sulfur-based therapeutics for rare ...
New test could save lives of patients with deadly fungal infection that spiked during pandemic
A new lateral-flow test could one day save lives across the world through early detection of a deadly fungal disease that ...
Tisento’s MELAS treatment receives fast track status from FDA
People living with MELAS and their families face tremendous challenges and deserve to have treatments that address the ...
Gene therapy successfully lowers eye pressure in mice, offering reversible alternative to daily glaucoma drops
Gene editing could be used to treat millions of glaucoma patients. Glaucoma is a leading cause of blindness, characterized by ...
Thiogenesis Announces Second Site Begins Enrolling in Phase 2 MELAS Clinical Trial and Provides Update
Thiogenesis Therapeutics, Corp. (TSXV: TTI) (OTCQX: TTIPF) ("Thiogenesis" or the "Company") a clinical-stage biopharmaceutical company developing sulfur-based therapeutics for serious pediatric and ...
TMCnet5d
Tisento Therapeutics Receives U.S. FDA Fast Track Designation for Zagociguat for the Treatment of MELAS
A first-in-class, brain-penetrant sGC stimulator, zagociguat is hypothesized to rebalance dysregulated cellular pathways in MELAS. By restoring cellular functions that support mitochondria, zagociguat ...